## Nulojix® (belatacept) Referral Form





| PATIENT INFORMATION  | Referral Status:                    | New Referral   | Updated Refe  | erral Referral Renewal  |  |
|--|-------------------------------------|--|---|---|--|
| DOB: Patient Name:   |                                     | Patient Phone:   |   |   |  |
| Patient Address:   |                                     | Patient Email:   |   |   |  |
| NKDA Allergies:  |                                     |  | Weight (lbs/kg):  | Height:   |  |
| ICD-10 Code (required): ICD-10 Description:  | Last Treatm                         | Last Treatment Date: Last 4 Digits SSN:  |   |   |  |
| PROVIDER INFORMATION   |                                     |  |   |   |  |
| Referral Coordinator Name:   | Referral Coo                        | Referral Coordinator Email:  |   |   |  |
| Ordering Provider:   | Provider NP                         | Provider NPI:  |   |   |  |
| Referring Practice Name:   | Phone:                              |  | Fax:  |   |  |
| Practice Address:  | City:                               |  | State:  | Zip Code:   |  |
| Physician Preferred Method of Contact: Email:  | F                                   | ax:  |   | Phone:  |  |
| NURSING  ☑ Infusion to be administered per Vivo protocols.   | NULOJIX                             | NULOJIX THERAPY ADMINISTRATION   |   |   |  |
| LABORATORY ORDERS  CBC at each dose every CMP at each dose every CRP at each dose every OTHER  REQUIRED DOCUMENTATION  Patient Demographics Insurance Card/Information  Progress Notes Supporting DX  Current Medication List and H&P  EBV Seropositive  | tra  Ma the Cro mg Dose modij to ne | intenance Dosing on every 4 weeks assover Dosing: 5 /kg every 4 week based on actual bodied if there is a chararest 12.5 mg. | of weeks 8 and g: 5 mg/kg at end (+/-3 days) mg/kg on days 1 s dy weight of patien nge in body weight | y 5 end of week 2 and week 4 after 12 after transplantation d of week 16 after transplantation, 1, 15, 29, 43 and 57 followed by 5 at at time of transplant. Dose will be to f greater than 10%. Dose rounded |  |
| *Consider administering premedication for prophylaxis against infusion research to the second | eactions and hypersens              | itivity reactions. **  | Order is valid for o  | Date  |  |
| mail Referrals To: referrals@vivoinfusion.com OR Fax Below Have a Question? Call (720) 902-4111  |                                     |  |   |   |  |

 Colorado: 303-418-4679
 Michigan: 833-957-2188
 New York: 800-540-1852
 Texas: 469-340-0044

 Connecticut: 203-724-4838
 Minnesota: 763-290-0903
 Ohio: 216-400-0674
 Virginia: 804-500-5941

 Florida: 904-930-4211
 Nevada: 702-489-5744
 Oklahoma: 918-770-4421
 Wisconsin: 414-600-5383

Massachusetts: 781-202-1629 New Jersey: 609-955-3711 Pennsylvania: 215-399-9244